Abbott Laboratories reported Q4 2025 organic sales growth of 3.8%, driven by a 10.5% increase in Medical Devices, while Nutrition faced volume declines due to price sensitivity. Adjusted EPS grew 12% to $1.50, with operating margins expanding 150 basis points to 25.8%. For 2026, the company guides for organic sales growth of 6.5% to 7.5% and adjusted EPS growth of 10% (midpoint $5.675), despite near-term headwinds in Nutrition. Key performance drivers include double-digit growth in Diabetes Care (CGM sales >$7.5B) and robust device pipelines, offset by a strategic reset in Nutrition to reignite volume through pricing and innovation. The pending acquisition of Exact Sciences is expected to close in late February, adding a high-growth cancer diagnostics vertical.
| Metric | Value | Change |
|---|---|---|
| Q4 Organic Sales Growth | 3.8% | +3.8% |
| Q4 Adjusted EPS | $1.50 | +12% |
| Q4 Adjusted Operating Margin | 25.8% | +150 bps |
| FY 2025 CGM Sales | >$7.5B | +17% |
| FY 2026 Guidance EPS | $5.55-$5.80 | +10% midpoint |
| FY 2026 Guidance Sales Growth | 6.5%-7.5% | N/A |
Abbott is aggressively shifting its Nutrition business from price-driven growth to volume-driven growth. Facing consumer price sensitivity, the company implemented price and promotion initiatives in Q4 and plans to launch eight new products in the next year. While this creates near-term headwinds (expected return to growth in H2 2026), management views this as essential for long-term sustainability, stating, 'The longer we took to make this change, the more painful it would be.'
The company is leveraging a deep pipeline to sustain double-digit growth in Medical Devices. Key catalysts include the U.S. launch of the Volt PFA catheter and Tactiflex Duo, the expansion of the Aveir leadless pacemaker (10% penetration in a $5B market), and structural heart products like Navitor and TriClip. Ford highlighted that the 'portfolio that we've assembled combined with the resilience of what this team has done... I've got high expectations.'
The pending acquisition of Exact Sciences is a transformative move to enter the cancer diagnostics market. Management expects to close the deal with a shareholder vote on Feb 20, projecting a post-close leverage ratio of 2.7x. This adds a high-growth vertical (~15% growth) to Abbott's portfolio, with specific excitement around Multi-Cancer Early Detection (MCED) testing potential.
After significant headwinds from Volume-Based Procurement (VBP) in 2025, management expects the diagnostic business in China to stabilize in 2026. The 'bulk' of VBP impact is behind them, with future categories having smaller market share for Abbott. This sets the stage for an acceleration in Core Lab Diagnostics growth, which grew 3.5% in Q4 and 7% ex-China for the full year.
The Nutrition business is facing a 'broad challenge' with volume growth suppressed by price increases necessitated by higher commodity costs. Management admitted the previous path was 'not sustainable,' signaling a risk that the pivot to volume growth may take longer or cost more than anticipated if consumer price sensitivity persists.
While the worst of VBP may be over, the diagnostics business in China remains a wildcard. Management noted they are 'not expecting big growth' and only need it to be 'pretty stable,' implying low expectations for this significant market despite global strength.
The strategy relies heavily on 'early signs' of success from price testing done just before Thanksgiving. If the new price/promotion balance fails to reignite volume quickly, the 'six-month process' to fix the business could drag on, impacting the H2 2026 recovery thesis.
Overall: Management displayed a confident and pragmatic demeanor, acknowledging near-term challenges in Nutrition while emphasizing strong execution in Medical Devices and Diagnostics. Robert Ford was direct about the need to change strategy in Nutrition to ensure long-term sustainability, while expressing high enthusiasm for the pipeline and the Exact Sciences acquisition.
Confidence: HIGH - Management reaffirmed double-digit EPS growth targets for 2026 despite Nutrition headwinds, citing robust device growth, pipeline productivity, and the Exact Sciences deal. Ford explicitly stated, 'I feel good about us closing Exact Sciences' and 'I've got high expectations for this business this year.'
$5.55 to $5.80 (10% growth at midpoint)
6.5% to 7.5%
15% to 16%
$1.12 to $1.18
Hedging & Uncertainty: Management used temporal hedges regarding the Nutrition recovery, stating it is a 'six-month process' and that they will 'keep monitoring that.' Ford used probability hedging on the Exact Sciences deal ('I'm not changing any assumption regarding timing') and the non-insulin CGM reimbursement ('I'm not baking that into my guidance'). However, confidence was high on device execution, using definitive language like 'I've got high expectations' and 'I feel good.'
This path is not sustainable long-term, so we began to make changes in the fourth quarter. - Robert Ford, CEO
I don't consider growing a billion dollars every single year and doing it four years in a row to be slowing down here. - Robert Ford, CEO
We expect 2026 to be another year powered by innovation, operational excellence, and strategic execution. - Robert Ford, CEO
I think there's a lot to like here. I think there's a lot of growth here. - Robert Ford, CEO
I think the way I see this is... after a certain age, I believe that if the product is right, performs right, and it's priced the right way, I just envision this being that type of test. - Robert Ford, CEO
Analyst Sentiment: Analysts were focused on the sustainability of growth given the Nutrition headwinds and the deceleration in top-line guidance relative to prior consensus. Questions were probing regarding the specific mechanics of the Nutrition turnaround and the cadence of recovery.
Management Responses: Ford was direct and detailed, taking a 'show, don't just tell' approach by explaining the specific pricing tests conducted. He pushed back firmly against narratives of slowing growth in Diabetes and Diagnostics, framing them as market share gains and volume expansion opportunities.
Nutrition volume recovery strategy and pricing mechanics.
Exact Sciences acquisition integration and dilution impact.
CGM market growth and non-insulin reimbursement potential.
China diagnostics outlook and VBP stabilization.
Pipeline catalysts including PFA (Volt) and Rhythm Management (Aveir).
Abbott remains a premier diversified medtech name with a robust pipeline driving double-digit EPS growth. The near-term volatility in Nutrition creates a buying opportunity, as the core businesses (Diabetes, CV, Diagnostics) are accelerating or sustaining high growth. The Exact Sciences acquisition adds a high-growth vertical that diversifies revenue and strengthens the diagnostics portfolio. Management's confidence in the H2 2026 recovery and the 10% EPS growth target supports a positive outlook.
Management noted that higher prices in Nutrition are 'suppressing demand as consumers become increasingly more price-sensitive,' reflecting broader CPG trends impacting volume.
The 'bulk' of Volume-Based Procurement headwinds in Diagnostics are over, moving from a major negative to a stable/low growth environment.
Ford stated, 'I would be extremely surprised if you hear that volumes were short in Q4,' indicating a robust procedural environment for MedTech despite macroeconomic concerns.